Beijing SL Pharmaceutical Co Ltd (002038) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Beijing SL Pharmaceutical Co Ltd (002038) has a cash flow conversion efficiency ratio of 0.012x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥66.55 Million ≈ $9.74 Million USD) by net assets (CN¥5.70 Billion ≈ $834.20 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 002038 company net worth for the company's overall valuation and market capitalisation.
Beijing SL Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Beijing SL Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Beijing SL Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beijing SL Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Explore Beijing SL Pharmaceutical Co Ltd cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SUPERLOOP LTD
F:9SL
|
N/A |
|
S.J.S. Enterprises Limited
NSE:SJS
|
0.122x |
|
MFA Financial Inc
NYSE:MFA
|
0.073x |
|
Mishra Dhatu Nigam Limited
NSE:MIDHANI
|
0.007x |
|
Hedef Holdings AS
IS:HEDEF
|
0.025x |
|
Aoyuan Beauty Valley Technology Co Ltd
SHE:000615
|
-0.002x |
|
Power HF Co Ltd
SHG:605100
|
0.060x |
|
BW OFFSHORE LTD. DL 050
F:XY81
|
0.083x |
Annual Cash Flow Conversion Efficiency for Beijing SL Pharmaceutical Co Ltd (2003–2025)
The table below shows the annual cash flow conversion efficiency of Beijing SL Pharmaceutical Co Ltd from 2003 to 2025. View Beijing SL Pharmaceutical Co Ltd stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥5.19 Billion ≈ $759.25 Million |
CN¥257.66 Million ≈ $37.70 Million |
0.050x | +22.90% |
| 2024-12-31 | CN¥5.58 Billion ≈ $816.62 Million |
CN¥225.49 Million ≈ $33.00 Million |
0.040x | -48.99% |
| 2023-12-31 | CN¥5.81 Billion ≈ $850.19 Million |
CN¥460.20 Million ≈ $67.34 Million |
0.079x | +11.33% |
| 2022-12-31 | CN¥5.48 Billion ≈ $801.78 Million |
CN¥389.82 Million ≈ $57.04 Million |
0.071x | -18.44% |
| 2021-12-31 | CN¥5.33 Billion ≈ $779.39 Million |
CN¥464.63 Million ≈ $67.99 Million |
0.087x | +4.57% |
| 2020-12-31 | CN¥4.98 Billion ≈ $729.42 Million |
CN¥415.84 Million ≈ $60.85 Million |
0.083x | -39.59% |
| 2019-12-31 | CN¥4.82 Billion ≈ $705.49 Million |
CN¥665.83 Million ≈ $97.43 Million |
0.138x | +28.62% |
| 2018-12-31 | CN¥4.52 Billion ≈ $661.20 Million |
CN¥485.17 Million ≈ $71.00 Million |
0.107x | +21.25% |
| 2017-12-31 | CN¥4.30 Billion ≈ $629.14 Million |
CN¥380.72 Million ≈ $55.71 Million |
0.089x | -12.31% |
| 2016-12-31 | CN¥3.93 Billion ≈ $575.09 Million |
CN¥396.86 Million ≈ $58.07 Million |
0.101x | -27.73% |
| 2015-12-31 | CN¥3.61 Billion ≈ $528.73 Million |
CN¥504.87 Million ≈ $73.88 Million |
0.140x | -4.41% |
| 2014-12-31 | CN¥3.18 Billion ≈ $465.50 Million |
CN¥465.00 Million ≈ $68.04 Million |
0.146x | +8.93% |
| 2013-12-31 | CN¥2.59 Billion ≈ $378.85 Million |
CN¥347.41 Million ≈ $50.84 Million |
0.134x | -28.91% |
| 2012-12-31 | CN¥2.11 Billion ≈ $308.98 Million |
CN¥398.60 Million ≈ $58.33 Million |
0.189x | +39.20% |
| 2011-12-31 | CN¥1.69 Billion ≈ $246.66 Million |
CN¥228.59 Million ≈ $33.45 Million |
0.136x | -31.02% |
| 2010-12-31 | CN¥1.21 Billion ≈ $177.26 Million |
CN¥238.13 Million ≈ $34.85 Million |
0.197x | +10.81% |
| 2009-12-31 | CN¥983.06 Million ≈ $143.85 Million |
CN¥174.41 Million ≈ $25.52 Million |
0.177x | -30.38% |
| 2008-12-31 | CN¥762.61 Million ≈ $111.59 Million |
CN¥194.32 Million ≈ $28.44 Million |
0.255x | +59.16% |
| 2007-12-31 | CN¥551.93 Million ≈ $80.76 Million |
CN¥88.36 Million ≈ $12.93 Million |
0.160x | +18.56% |
| 2006-12-31 | CN¥426.20 Million ≈ $62.37 Million |
CN¥57.55 Million ≈ $8.42 Million |
0.135x | +8.78% |
| 2005-12-31 | CN¥382.49 Million ≈ $55.97 Million |
CN¥47.48 Million ≈ $6.95 Million |
0.124x | +43.52% |
| 2004-12-31 | CN¥361.45 Million ≈ $52.89 Million |
CN¥31.26 Million ≈ $4.57 Million |
0.086x | -67.43% |
| 2003-12-31 | CN¥115.05 Million ≈ $16.84 Million |
CN¥30.55 Million ≈ $4.47 Million |
0.266x | -- |
About Beijing SL Pharmaceutical Co Ltd
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People's Republic of China and internationally. The company's finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; paclitaxel injection; docetaxel injection; thymopentin; vinorelbine tartrate injection; hydroxyl-camptothec… Read more